Literature DB >> 10070858

Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6.

J Kurebayashi1, T Otsuki, C K Tang, M Kurosumi, S Yamamoto, K Tanaka, M Mochizuki, H Nakamura, H Sonoo.   

Abstract

A new human breast cancer cell line, KPL-4, was recently isolated from the malignant pleural effusion of a breast cancer patient with an inflammatory skin metastasis. This cell line can be cultured under serum-free conditions and is tumorigenic in female athymic nude mice. Flow cytometric analysis revealed the expression of Erb B-1, -2 and -3. Dot blot hybridization showed a 15-fold amplification of the erb B-2. Reverse transcription-polymerase chain reaction analysis showed a detectable level of mRNA expression of all the Erb B family receptors. In addition, all the receptors were autophosphorylated under a serum-supplemented condition. Unexpectedly, transplanted KPL-4 tumours induced cachexia of recipient mice. A high concentration of interleukin-6 (IL-6) was detected in both the culture medium and the serum of mice. The weight of tumours significantly correlated with the serum IL-6 level. The antiproliferative effect of a humanized anti-Erb B-2 monoclonal antibody, rhuMAbHER2, was investigated. This antibody significantly inhibited the growth of KPL-4 cells in vitro but modestly in vivo. Loss of mouse body weight was partly reversed by rhuMAbHER2. These findings suggest that KPL-4 cells may be useful in the development of new strategies against breast cancer overexpressing the Erb B family receptors and against IL-6-induced cachexia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10070858      PMCID: PMC2362677          DOI: 10.1038/sj.bjc.6690114

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  64 in total

1.  HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis.

Authors:  Zachary C Hartman; Xiao-Yi Yang; Oliver Glass; Gangjun Lei; Takuya Osada; Sandeep S Dave; Michael A Morse; Timothy M Clay; Herbert K Lyerly
Journal:  Cancer Res       Date:  2011-04-25       Impact factor: 12.701

2.  Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness.

Authors:  Eric Hesse; Saskia Schröder; Diana Brandt; Jenny Pamperin; Hiroaki Saito; Hanna Taipaleenmäki
Journal:  JCI Insight       Date:  2019-04-09

3.  Site-Selective Antibody Functionalization via Orthogonally Reactive Arginine and Lysine Residues.

Authors:  Dobeen Hwang; Napon Nilchan; Alex R Nanna; Xiaohai Li; Michael D Cameron; William R Roush; HaJeung Park; Christoph Rader
Journal:  Cell Chem Biol       Date:  2019-06-20       Impact factor: 8.116

4.  Stepwise movements in vesicle transport of HER2 by motor proteins in living cells.

Authors:  Tomonobu M Watanabe; Hideo Higuchi
Journal:  Biophys J       Date:  2007-03-16       Impact factor: 4.033

5.  3D rotational motion of an endocytic vesicle on a complex microtubule network in a living cell.

Authors:  Seohyun Lee; Hideo Higuchi
Journal:  Biomed Opt Express       Date:  2019-11-27       Impact factor: 3.732

6.  Stable and Potent Selenomab-Drug Conjugates.

Authors:  Xiuling Li; Christopher G Nelson; Rajesh R Nair; Lori Hazlehurst; Tina Moroni; Pablo Martinez-Acedo; Alex R Nanna; David Hymel; Terrence R Burke; Christoph Rader
Journal:  Cell Chem Biol       Date:  2017-03-16       Impact factor: 8.116

7.  Development of a 5-plex SILAC method tuned for the quantitation of tyrosine phosphorylation dynamics.

Authors:  Manuel Tzouros; Sabrina Golling; David Avila; Jens Lamerz; Marco Berrera; Martin Ebeling; Hanno Langen; Angélique Augustin
Journal:  Mol Cell Proteomics       Date:  2013-07-23       Impact factor: 5.911

8.  Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.

Authors:  Dongwei Zhang; Tiffany A LaFortune; Savitri Krishnamurthy; Francisco J Esteva; Massimo Cristofanilli; Ping Liu; Anthony Lucci; Balraj Singh; Mien-Chie Hung; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

9.  Dynamics of different-sized solid-state nanocrystals as tracers for a drug-delivery system in the interstitium of a human tumor xenograft.

Authors:  Masaaki Kawai; Hideo Higuchi; Motohiro Takeda; Yoshio Kobayashi; Noriaki Ohuchi
Journal:  Breast Cancer Res       Date:  2009-07-03       Impact factor: 6.466

10.  Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.

Authors:  T Gelardi; V Damiano; R Rosa; R Bianco; R Cozzolino; G Tortora; P Laccetti; G D'Alessio; C De Lorenzo
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.